Fennec Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FENC research report →
Range $16 – $19
Price Chart
About the company
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate.
- CEO
- Jeffrey S. Hackman
- IPO
- 2017
- Employees
- 35
- HQ
- Research Triangle Park, NC, US
Get TickerSpark's AI analysis on FENC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $479.44M
- P/E
- 593.01
- Fwd P/E
- 41.15
- PEG
- 4.20
- P/S
- 7.22
- P/B
- 9.69
- EV/EBITDA
- 162.67
- Div Yield
- 0.00%
- Gross Margin
- 94.13%
- Op Margin
- 5.56%
- Net Margin
- 3.05%
- ROE
- 4.92%
- ROIC
- 4.25%
Latest fiscal year · YoY change
- Revenue
- $44.64M-6.1%
- Gross Profit
- $40.88M-7.8%
- Op Income
- $-6,346,000
- Net Income
- $-9,741,000-2134.2%
- EPS
- $-0.36-2150.0%
- OCF Growth
- -146.2%
- FCF Growth
- -146.2%
- Beta
- 1.21
- RSI (14)
- 70
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Fennec delivered its best commercial quarter ever, with PEDMARK sales up sharply year over year and management pointing to stronger field execution, record patient activity, and a healthier fourth-quarter carryover.· November 12, 2026
- Net product sales were $19.4 million, up about 56% year over year from $12.5 million in Q3 2025.
- Non-GAAP adjusted EBITDA was a record $5.8 million, or 30% of net product sales, versus $2.0 million a year ago.
- Patient enrollments in Fennec HEARS rose 23% sequentially and completed infusions increased 58% versus Q2, helping drive a record quarter.
- Management said Q4 entered with the largest planned infusion/vial carryover in company history and strong October visibility.
- Commercial gains were driven by Project Ignite, GPO/data-driven targeting, and new formulary wins at academic centers, while evidence-generation programs are starting to add clinical support.
Fennec reported third-quarter 2026 net product sales of $19.4 million, compared with $12.5 million in Q3 2025, an increase of approximately 56% year over year. EPS was $0.12 per share versus a loss of $0.02 per share in the comparable quarter last year. Non-GAAP adjusted EBITDA was about $5.8 million, or 30% of net product sales, versus $2.0 million a year ago and $2.8 million in Q2 2026. Cash OpEx was approximately $12.7 million, up about $3 million year over year, and cash from operations was nearly $7 million, a record. Cash and cash equivalents were $48.7 million at September 30, 2026, with no debt. For guidance, management said Q4 2026 cash OpEx should be the lowest of the year and full-year cash OpEx should be in the low $50 millions; they also said Q4 has strong visibility thanks to carryover from Q3 and a strong October.
Jeffrey Hackman emphasized that the company is seeing the payoff from commercial investments made earlier in 2026, especially Project Ignite, which expanded the sales force into 14 territories with 4 frontline managers. He highlighted double-digit quarter-over-quarter commercial demand growth, record HEARS enrollments and infusions, and stronger traction in both community and academic settings. On the science side, he pointed to investigator-sponsored trial data in Japan and upcoming City of Hope presentations as important steps in broadening PEDMARK’s evidence base beyond pediatric AYA use. His tone was upbeat and confident, but he repeatedly framed the strategy as disciplined execution rather than speculation.
Robert Andrade said this was Fennec’s best commercial quarter ever and stressed the company’s operating leverage. He cited net product sales of $19.4 million, adjusted EBITDA of $5.8 million, nearly $7 million in cash from operations, and cash of $48.7 million with no debt. He noted that cash OpEx was about $12.7 million, with Q4 expected to be the lowest cash OpEx quarter of the year and full-year cash OpEx likely in the low $50 millions. He also said the company has strong visibility into Q4 because of the large carryover from Q3 and a strong October.
Analysts focused on why enrollments rose faster than revenue, and management said the gap reflects timing between enrollment and infusion plus differences in patient mix, while emphasizing that enrollments are the best leading KPI. They also pressed on the large Midwestern academic center win; management said it was a major formulary win, contributed some in Q3 but will matter much more in Q4, and was driven by coordinated work across market access, commercial, medical, and KOL engagement. Questions about infusion conversion and adherence drew the response that the patient journey typically runs 4-6 months and the team is working to improve continuation and reduce discontinuation. On Japan and NCCN, Hackman said the company is actively pursuing licensing discussions in Japan but wants a deal that is good for Fennec, and he would not predict NCCN timing, though he expects upcoming IST data to inform the discussion.
The bull case from this call is that PEDMARK appears to be gaining real commercial traction, with record sales, record EBITDA, and strong sequential patient activity. Management believes the expanded sales force, data-driven targeting, and formulary wins are creating a durable growth engine, while upcoming clinical presentations could broaden the market beyond the current pediatric/AYA base.
The main risks are that revenue still depends on conversion from enrollment to infusion and on sustained adherence over a 4-6 month patient journey, so timing can create quarter-to-quarter volatility. Management also acknowledged that the large academic-center win was not a major Q3 revenue contributor yet, NCCN adult expansion is uncertain, and Japan licensing remains unresolved and dependent on finding the right partner and terms.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 48.4%
- Shares Outstanding
- 35.31M
- Float Shares
- 17.10M
of shares held by institutions
109 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Rosalind Advisors, Inc. | 3.19M | ▲ 279.80K |
| Aigh Capital Management LLC | 2.50M | ▲ 13.38K |
| Blackrock, Inc. | 2.03M | ▲ 306.33K |
| Solas Capital Management, LLC | 1.89M | ▼ 592.83K |
| Awm Investment Company, Inc. | 1.16M | 0 |
| Vanguard Group Inc | 1.07M | ▲ 111.89K |
| Vanguard Capital Management LLC | 839.31K | 0 |
| Prospect Capital Advisors, LLC | 497.80K | ▲ 497.80K |
| State Street Corp | 425.69K | ▼ 315 |
| Geode Capital Management, LLC | 409.06K | ▲ 6.50K |
| Essex Investment Management Co LLC | 318.77K | ▲ 318.77K |
| Centerbook Partners LP | 304.95K | ▲ 186.37K |
Held by 62 ETFs
Biggest fund positions in FENC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 31, 26 | Evans Terry L | other | 168 |
| Oct 31, 26 | Sayad Pierre Sargis | other | 168 |
| Oct 31, 26 | Hackman Jeffrey S. | other | 1,159 |
| Oct 31, 26 | Cioffi Christiana Marie | other | 156 |
| Oct 31, 26 | Andrade Robert | other | 1,703 |
| Oct 12, 26 | Sayad Pierre Sargis | other | 3,846 |
| Oct 12, 26 | Hackman Jeffrey S. | other | 2,224 |
| Oct 12, 26 | Evans Terry L | other | 2,326 |
| Oct 12, 26 | Cioffi Christiana Marie | other | 3,946 |
| Oct 12, 26 | Andrade Robert | other | 3,846 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FENC coverage
Recent articles, reports, and earnings notes.
No research on FENC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FENC report →